Septerna, Inc.
About Septerna, Inc.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $46.0M
- Net income
- -$48.9M
- Total assets
- $596.2M
- Market cap
- $1.4B
- Operating margin
- -148.6%
- Net margin
- -106.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $46.0M
- Operating expenses
- $114.2M
- Operating income
- -$68.3M
- Income tax
- $12.0K
- Net income
- -$48.9M
- EPS (basic)
- $-1.10
- EPS (diluted)
- $-1.10
Balance sheet
- Total assets
- $596.2M
- Current assets
- $411.0M
- Total liabilities
- $214.3M
- Current liabilities
- $86.9M
- Shareholders’ equity
- $381.9M
Cash flow
- Operating cash flow
- $110.2M
- Investing cash flow
- -$229.4M
- Financing cash flow
- $1.7M
- Net cash flow
- -$117.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.4B
- EPS (diluted)
- $-1.1
- Shares outstanding
- 46.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 25, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $48.9M in FY2025.
- Revenue grew 4175% from FY2024 to FY2025.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Septerna, Inc..
Write a review
News about Septerna, Inc.
News & sentiment via Polygon.io
